(0)サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1587544

過敏性腸症候群治療の市場規模、シェア、分析レポート：タイプ別、製品別、流通チャネル別、地域別、セグメント別予測、2025年～2030年

Irritable Bowel Syndrome Treatment Market Size, Share & Analysis Report By Type (IBS-C, IBS-D), By Product (Xifaxan, Linzess/Constella, Viberzi, Amitiza), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
過敏性腸症候群治療の市場規模、シェア、分析レポート：タイプ別、製品別、流通チャネル別、地域別、セグメント別予測、2025年～2030年
出版日: 2024年10月10日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

過敏性腸症候群治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、過敏性腸症候群治療の世界市場規模は2025年から2030年にかけてCAGR 8.8％を記録し、2030年には60億2,000万米ドルに達すると予測されています。

対象疾患の有病率の上昇と既存薬の適応拡大が市場成長を加速させる可能性が高いです。さらに、薬剤の普及と新製品の発売が過敏性腸症候群（IBS）治療市場を牽引すると予測されます。

IBSは最も一般的な胃腸疾患のひとつで、世界の有病率は通常10～15％です。IBS患者の大半は50歳未満ですが、高齢者も多く苦しんでいます。症状の影響は、軽度の不都合から深刻な衰弱までさまざまです。IBSは患者の仕事、感情、社会生活のさまざまな面を支配する可能性があります。中等度から重度の患者は通常、感情的、身体的、教育的、社会的、経済的な幸福を頻繁に損なう症状と闘っています。

症状はさまざまで、時には矛盾し、便秘と下痢が交互に起こることもあります。長期にわたる症状は、患者の仕事や個人的な活動を妨げ、通常、個人の可能性を制限します。これらの要因により、過敏性腸症候群の治療の必要性はさらに高まり、患者は規則正しい生活を送ることができるようになります。

患者の約40％が軽度のIBS、35％が中等度のIBS、25％が重度のIBSです。IBSの症状を見分けられない人はかなり多く、現在でも医師が診断する最も一般的な疾患のひとつです。IBSの症状を持つすべての人が治療を受けるわけではないです。しかし、米国だけでも過敏性腸症候群で年間240万～350万人の医師が受診しています。世界的には、男性の約35～40％、女性の約60～65％が罹患しています。

過敏性腸症候群治療市場レポート・ハイライト

  • IBS-C分野は、有病率の増加とリンゼス（リナクロチド）やアミティーザ（ルビプロストン）などの効果的な薬剤の採用増加により、予測期間中にCAGR 11.9%で成長すると予測されます。
  • IBS-D領域は、診断症例の増加とQOLへの影響に対する理解の高まりにより、2024年に49.8%の最大売上シェアで市場を独占しました。
  • リンゼス／Constellaが市場を席巻し、2024年に37.3%の最大売上シェアを占めました。
  • 病院薬局が市場をリードし、2024年に最大の収益シェアを占めました。これは、その包括的なインフラと統合された患者ケアシステムに起因します。
  • 北米の過敏性腸症候群（IBS）治療市場は世界市場を独占し、2024年には37.5％の最大収益シェアを占めました。
  • 欧州の過敏性腸症候群治療市場の成長は、消化器疾患の汚名を返上することを目的とした啓発キャンペーンの増加によって牽引されています。ドイツや英国などの国々では、IBSの症状や利用可能な治療法に関する患者の関与が増加しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 過敏性腸症候群治療市場の変数、動向、範囲

  • 市場イントロダクション/系統展望
  • 市場規模と成長見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 過敏性腸症候群治療市場分析ツール
    • ポーターの分析
    • PESTEL分析

第4章 過敏性腸症候群治療市場：タイプの推定・動向分析

  • タイプ別市場シェア、2024年と2030年
  • タイプセグメントダッシュボード
  • 市場規模と予測および動向分析、タイプ別、2018～2030年
  • IBS-C
  • IBS-D

第5章 過敏性腸症候群治療市場： 薬剤クラスの推定・動向分析

  • 薬物クラス市場シェア、2024年および2030年
  • 薬物クラスセグメントダッシュボード
  • 市場規模と予測および動向分析、薬剤クラス別、2018～2030年
  • シファクサン
  • リンゼス/コンステラ
  • ヴィベルジ
  • アミティザ
  • その他

第6章 過敏性腸症候群治療市場：流通チャネルの推定・動向分析

  • 流通チャネル市場シェア、2024年および2030年
  • 流通チャネルセグメントダッシュボード
  • 市場規模と予測および動向分析、流通チャネル別、2018年から2030年
  • 病院薬局
  • 小売薬局
  • その他

第7章 過敏性腸症候群治療市場：地域の推定・動向分析

  • 地域別市場シェア分析、2024年および2030年
  • 地域市場ダッシュボード
  • 市場規模、予測動向分析、2018年から2030年：
  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
  • アジア太平洋
    • 中国
    • 日本
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東およびアフリカ
    • 南アフリカ

第8章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル
    • Ironwood Pharmaceuticals, Inc.
    • Allergan
    • Astellas Pharma, Inc.
    • Takeda Pharmaceutical Company Limited
    • AstraZeneca
    • Sanofi SA
    • Sebela Pharmaceuticals Inc
    • Bausch Health
    • Synthetic Biologics, Inc
    • Ardelyx
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Irritable Bowel Syndrome Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 5 Global Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 6 Global Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Irritable Bowel Syndrome Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 9 North America Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 10 North America Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S. Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 12 U.S. Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 13 U.S. Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Canada Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 16 Canada Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Europe Irritable Bowel Syndrome Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 18 Europe Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 19 Europe Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 20 Europe Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 UK Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 22 UK Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 23 UK Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 Germany Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 25 Germany Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 26 Germany Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 France Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 28 France Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 29 France Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 Italy Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 31 Italy Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 32 Italy Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Spain Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 34 Spain Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 35 Spain Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Irritable Bowel Syndrome Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 37 Asia Pacific Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 38 Asia Pacific Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Japan Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 41 Japan Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 42 Japan Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 China Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 44 China Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 45 China Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Latin America Irritable Bowel Syndrome Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 47 Latin America Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 48 Latin America Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 49 Latin America Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 Brazil Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 51 Brazil Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 52 Brazil Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 Argentina Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 54 Argentina Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 55 Argentina Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Irritable Bowel Syndrome Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 59 Middle East & Africa Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 South Africa Irritable Bowel Syndrome Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 61 South Africa Irritable Bowel Syndrome Treatment Market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 62 South Africa Irritable Bowel Syndrome Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Irritable Bowel Syndrome Treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Irritable bowel syndrome treatment market dynamics
  • Fig. 12 Irritable bowel syndrome treatment market: Porter's five forces analysis
  • Fig. 13 Irritable bowel syndrome treatment market: PESTLE analysis
  • Fig. 14 Irritable bowel syndrome treatment market: Type segment dashboard
  • Fig. 15 Irritable bowel syndrome treatment market: Type market share analysis, 2024 & 2030
  • Fig. 16 IBS-C market, 2018 - 2030 (USD Million)
  • Fig. 17 IBS-D market, 2018 - 2030 (USD Million)
  • Fig. 18 Irritable bowel syndrome treatment market: Drug class segment dashboard
  • Fig. 19 Irritable bowel syndrome treatment market: Drug class market share analysis, 2024 & 2030
  • Fig. 20 Xifaxan market, 2018 - 2030 (USD Million)
  • Fig. 21 Linzess/Constella market, 2018 - 2030 (USD Million)
  • Fig. 22 Viberzi market, 2018 - 2030 (USD Million)
  • Fig. 23 Amitiza market, 2018 - 2030 (USD Million)
  • Fig. 24 Others market, 2018 - 2030 (USD Million)
  • Fig. 25 Irritable bowel syndrome treatment market: Distribution Channel segment dashboard
  • Fig. 26 Irritable bowel syndrome treatment market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 27 Hospital pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 28 Retail pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 29 Others market, 2018 - 2030 (USD Million)
  • Fig. 30 Irritable bowel syndrome treatment market revenue, by region
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 North America irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 33 U.S. country dynamics
  • Fig. 34 U.S. irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 Canada country dynamics
  • Fig. 36 Canada irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Europe irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 UK country dynamics
  • Fig. 39 UK irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 Germany country dynamics
  • Fig. 41 Germany irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 France country dynamics
  • Fig. 43 France irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 Italy country dynamics
  • Fig. 45 Italy irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Spain country dynamics
  • Fig. 47 Spain irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 Asia Pacific irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Japan country dynamics
  • Fig. 50 Japan irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 China country dynamics
  • Fig. 52 China irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 Latin America irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Brazil country dynamics
  • Fig. 55 Brazil irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina country dynamics
  • Fig. 57 Argentina irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 MEA irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 South Africa country dynamics
  • Fig. 61 South Africa irritable bowel syndrome treatment market, 2018 - 2030 (USD Million)
  • Fig. 62 Company categorization
  • Fig. 63 Company market position analysis
  • Fig. 64 Strategic framework
目次
Product Code: GVR-3-68038-319-5

Irritable Bowel Syndrome Treatment Market Growth & Trends:

The global irritable bowel syndrome treatment market size is expected to reach USD 6.02 billion by 2030, registering a CAGR of 8.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of target disease and increasing label extension of existing drugs are likely to accelerate market growth. In addition, growing uptake of drugs and launch of novel products are anticipated to drive the irritable bowel syndrome (IBS) treatment market.

IBS is one of the most common gastrointestinal disorders, with the worldwide prevalence rate usually ranging between 10-15%. Most of the patients with IBS are under 50 years of age but many older adults suffer as well. The effect of the condition can vary from mild inconvenience to serious debilitation. It can control many facets of a patient's professional, emotional, and social life. Patients with moderate to severe conditions usually struggle with symptoms that frequently impair their emotional, physical, educational, social, and economic wellbeing.

Symptoms can vary and are sometimes contradictory, constipation can alternate with diarrhea. Long-term symptoms can disturb the patient's professional and personal activities, and usually limits an individual's potential.These factors further increase the need for irritable bowel syndrome treatment, which enable patients to go on with their regular life.

Around 40% patients have mild IBS, 35% have moderate IBS, and 25% have severe IBS. A significant number of people cannot distinguish IBS symptoms; it is still one of the most common disorders diagnosed by physicians. Not everyone with IBS symptoms pursues treatment for the same. Though, there are around 2.4-3.5 million yearly doctor visits for irritable bowel syndrome in U.S. alone. Globally, it affects around 35-40% of males and 60-65% of females.

Irritable Bowel Syndrome Treatment Market Report Highlights:

  • The IBS-C segment is expected to grow at a CAGR of 11.9% over the forecast period, owing to the increasing prevalence of this condition and the rising adoption of effective medications such as Linzess (linaclotide) and Amitiza (lubiprostone).
  • The IBS-D segment dominated the market with the largest revenue share of 49.8% in 2024 attributed to a rise in diagnosed cases and an increasing understanding of the condition's impact on quality of life.
  • Linzess/Constella dominated the market and accounted for the largest revenue share of 37.3% in 2024 attributed to its effectiveness in managing constipation-predominant IBS (IBS-C).
  • Hospital pharmacies led the market and accounted for the largest revenue share in 2024, which is attributed to their comprehensive infrastructure and integrated patient care systems.
  • North America irritable bowel syndrome (IBS) treatment market dominated the global market and accounted for the largest revenue share of 37.5% in 2024 attributed to the high prevalence of IBS and the increasing awareness of its management options.
  • The growth of Europe irritable bowel syndrome treatment market is driven by increasing awareness campaigns aimed at destigmatizing gastrointestinal disorders. Countries such as Germany and the UK are seeing increased patient engagement regarding IBS symptoms and available treatments.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Irritable Bowel Syndrome Treatment Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Irritable Bowel Syndrome Treatment Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Irritable Bowel Syndrome Treatment Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. IBS-C
    • 4.4.1. IBS-C Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. IBS-D
    • 4.5.1. IBS-D Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Irritable Bowel Syndrome Treatment Market: Drug Class Estimates & Trend Analysis

  • 5.1. Drug Class Market Share, 2024 & 2030
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 5.4. Xifaxan
    • 5.4.1. Xifaxan Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Linzess/Constella
    • 5.5.1. Linzess/Constella Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Viberzi
    • 5.6.1. Viberzi Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Amitiza
    • 5.7.1. Amitiza Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Irritable Bowel Syndrome Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2030
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel , 2018 to 2030 (USD Million)
  • 6.4. Hospital Pharmacy
    • 6.4.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Retail Pharmacy
    • 6.5.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Irritable Bowel Syndrome Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. China
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. China Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Japan
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. Japan Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Irritable Bowel Syndrome Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Ironwood Pharmaceuticals, Inc.
      • 8.5.1.1. Participant's Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Recent Developments/ Strategic Initiatives
    • 8.5.2. Allergan
      • 8.5.2.1. Participant's Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Recent Developments/ Strategic Initiatives
    • 8.5.3. Astellas Pharma, Inc.
      • 8.5.3.1. Participant's Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Recent Developments/ Strategic Initiatives
    • 8.5.4. Takeda Pharmaceutical Company Limited
      • 8.5.4.1. Participant's Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Recent Developments/ Strategic Initiatives
    • 8.5.5. AstraZeneca
      • 8.5.5.1. Participant's Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Recent Developments/ Strategic Initiatives
    • 8.5.6. Sanofi S.A
      • 8.5.6.1. Participant's Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Recent Developments/ Strategic Initiatives
    • 8.5.7. Sebela Pharmaceuticals Inc
      • 8.5.7.1. Participant's Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Recent Developments/ Strategic Initiatives
    • 8.5.8. Bausch Health
      • 8.5.8.1. Participant's Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Recent Developments/ Strategic Initiatives
    • 8.5.9. Synthetic Biologics, Inc
      • 8.5.9.1. Participant's Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Recent Developments/ Strategic Initiatives
    • 8.5.10. Ardelyx
      • 8.5.10.1. Participant's Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Recent Developments/ Strategic Initiatives